Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report

I. Sermet-Gaudelus, V. Stoven, J.P. Annereau, V. Witko-Sarsat, P. Reinert, M. Guyot, B. Descamps-Latscha, J.Y. Lallemand and G. Lenoir

Service de Pédiatrie II, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris; Laboratoire de Résonnance Magnétique Nucléaire, Ecole Polytechnique, Massy Palaiseau; INSERM U507, Hôpital Necker, Paris; Pediatric Department, Hôpital Intercommunal, Créteil; Pediatric Department, Hôpital de Lisieux, France

Corresponding Author
Tel: (+33) 1 44 49 48 83
Fax: (+33) 1 47 83 32 26
Email: gerard.lenoir@nck.ap-hop-paris.fr

Cystic fibrosis (CF) lung disease is characterized by persistent inflammation. Antiinflammatory drugs, such as corticosteroids and ibuprofen, have proved to slow the decline of pulmonary function although their use is limited because of frequent adverse events. We hypothesized that colchicine could be an alternative treatment because of its antiinflammatory properties and upregulatory effect on cystic fibrosis transmembrane regulator (CFTR) closely related proteins. We herein present results obtained in an open study of eight CF children treated with colchicine for at least 6 months. Clinical status was better in all patients and respiratory function tests significantly improved in five. Median duration of antibiotic therapy decreased significantly. These preliminary results support our hypothesis of a beneficial effect of colchicine in CF patients and stress the need for a controlled therapeutic trial.

Key words: Cystic Fibrosis, Inflammation, Cystic fibrosis transmembrane regulator, ABC protein, Colchicine

Introduction

Lung disease in cystic fibrosis (CF) patients is characterized by persistent bacterial infection leading to chronic bronchitis and bronchectasias. Vigorous antibiotherapy, clearance of mucus and adequate nutritional support have been the bases of conventional therapy. Recently, attention has been focused on the lung inflammation which not only damages the parenchyma directly but also impairs local defence against pathogens. Blunting the inflammatory response by using antiinflammatory drugs such as corticosteroids or ibuprofen has been proven to slow the decline of pulmonary function, although the high incidence of adverse events outweighs beneficial effect.

Colchicine should be considered as an alternative treatment because of its antiinflammatory properties notably by interference with PNN margination, chemotaxis and phagocytosis. Interestingly, colchicine has also been shown to upregulate the expression of the multi-drug-resistance (MDR) gene. This gene encodes for the P-glycoprotein or Pgp which belongs to the ATP binding cassette (ABC) protein family and shares remarkable homology with cystic fibrosis transmembrane regulator (CFTR). In vitro experiments have shown that closely related ABC proteins can complement each other. Taken together, these data led us to propose that colchicine might induce complementation of CFTR by P-gp.

Recently, we reported improvement of lung function in a CF patient after antitumoral therapy and suggested that this could be due to the complementation of CFTR. However the toxicity of these drugs precludes their wide use in CF patients. We herein present preliminary results showing that colchicine may exert a beneficial effect on CF clinical status.

Materials and methods

Patients

Eight patients with CF diagnosed according to conventional criteria entered this open study conducted from 1 March 1997 to 31 December 1997. All these patients had end-stage CF lung disease or chronic airflow limitation unresponsive to conventional therapy. Colchicine (Houdé, Paris, France) was administered orally (1 mg daily), during at least 6 moths without other antiinflammatory treatment (inhaled or oral steroid therapy, nonsteroidal antiinflammatory drugs) or recombinant human DNase.
The following parameters were considered every 3 months during the duration of the assay, i.e. at least 6 months: body weight (BW) and height (expressed as standard deviation from ideal weight and height for age); respiratory function tests (forced expiratory volume– FEV1, and forced vital capacity– FVC); number of antibiotic courses in relation to respiratory tract infections. Concomitant therapies and adverse clinical events were documented.

Statistics
Results are presented as median (range) values. The average values in the 6 months before the beginning of treatment were compared with their post-treatment average after completion of at least 6 months of treatment. Statistical analysis was done using Wilcoxon’s signed rank test. P value of less than 0.05 was considered significant.

Results
Patient characteristics
Eight patients (six boys) were studied. The characteristics of the patients at beginning of treatment are shown in Table 1. Median age was 13.5 years (range 5–28 years). Six patients were ΔF508 homozygous. Median FEV1 and FVC were respectively 54% (range 21–63%) and 62% (37–64%). Patient 7 was a 27-year-old patient with secondary nephropathic amyloidosis. The occurrence of renal failure justified the start of colchicine therapy. Patient 8 was a 13-year-old girl on the lung transplant waiting list because of a dramatic decline of respiratory function and nutritional status (Fig. 1). Patient 2 and patient 8 both also had concomitant long-term azithromycin started 2 years before.

Effect of colchicine on patient clinical status
Median duration of treatment was 7 months (range 6–12 months). No child had change in the baseline treatment during the study period. For all the patients there was a subjective improvement in clinical status. Median duration of antibiotherapy significantly decreased from 5 to 1.2 days per month (P < 0.05). Median weight gain was + 0.25 SD (P = 0.1).

The respiratory function tests could be performed in seven patients. FEV1 substantially improved in six patients, rising from 54% (21–63%) predicted to 57% (37–64%) predicted (P = 0.14). In contrast, FVC remained unchanged during the duration of colchicine therapy. Patient 8, on the lung transplant waiting list, had a marked improvement of FEV1 from 21% to 57% predicted, and FVC from 32% to 44% which prompted his removal from this list. Concomitantly, weight gain (4 kg) and reduced need for antibiotics (15 days during the 6 months after beginning of treatment versus 30 days during the 6 months before) were observed. The child had recovered good daily activity. It is worth noting that there had been no concomitant change in the usual treatment of this patient.

Adverse effects
The drug was well tolerated except in two patients who had mild diarrhoea. However, this mild side

Table 1. Baseline characteristics of patients before colchicine treatment

| Patient (No.) | Age (years) | BW* | CF mutation | FVC** | FEV1** | Lung colonization |
|---------------|-------------|-----|-------------|-------|--------|------------------|
| 1             | 10          | –0.5 | DF508/DF508 | 66%   | 54%    | P. aeruginosa    |
| 2             | 16          | –1   | DF508/DF508 | 65%   | 60%    | P. aeruginosa Staph. aureus B. Cepacia |
| 3             | 14          | –0.5 | DF508/DF508 | 81%   | 75%    | Staph. aureus    |
| 4             | 5           | –1.5 | ?            | ND    | ND     | P. aeruginosa Staph. aureus |
| 5             | 6           | –2   | DF508/DF508 | 66%   | 54%    | H. influenzae    |
| 6             | 13          | 0.5  | DF508/DF508 | 90%   | 92%    | P. aeruginosa    |
| 7             | 28          | –1   | DF508/DF508 | 72%   | 61%    | P. aeruginosa    |
| 8             | 14          | –2   | DF508/?      | 32%   | 32%    | P. aeruginosa B. Cepacia |
| Median        | 13.5        | –1   |              | 54    | 62     |                  |
| Range         | 5–28        | –2–0.5 |            | 21–63 | 32–68  |                  |

*Expressed as SD for theoretical weight for age; **Expressed as percentages of theoretical value for age and sex.
Colchicine in cystic fibrosis

Effect did not lead to discontinuation of the treatment.

Discussion

We report preliminary results showing that colchicine treatment in CF patients is associated with a significant decrease of antibiotic therapy, and a potential improvement of respiratory status. To our knowledge, colchicine has not yet been proposed in CF but interestingly, it has already been used for the treatment of idiopathic pulmonary fibrosis and IgE-mediated asthma. The beneficial effect of colchicine may be due to two different mechanisms: (i) colchicine has anti-inflammatory properties due to interference with PNN margination, chemotaxis and phagocytosis and inhibition of leukotriene synthesis. It also inhibits fibroblast proliferation and total collagen synthesis; (ii) colchicine also promotes expression of ABC proteins such as P-gp which shares great structural homology with CFTR. Several recent data also suggest functional homology. CFTR overexpression leads to a multidrug-resistance phenotype similar to P-gp. CFTR exports glutathione and glucuronate anions and may play a role in cell detoxification similar to MRP. As closely related ABC proteins can complement each other, upregulation of P-gp and/or MRP may hence lead to functional complementation of defective CFTR. This hypothesis is also supported by the expression of MDR in nasal epithelial cells of a CF patient treated with anti-tumorous drugs but not in a control CF patient who never had chemotherapy. This function of upregulation of ABC proteins could be emphasized by the adjunction of other ABC protein inducers such as azithromycin. Interestingly, two patients were treated by both drugs and experienced an improvement in clinical status.

In conclusion, colchicine should be considered in the treatment in CF patients, because of its anti-inflammatory role and its property of inducing ABC proteins. Although preliminary, the potential importance of these results in this severe disease seems to us to justify their early report and has formed the basis of a controlled trial which is now being undertaken by our group.

References

1. Koch C, Hoiby N. Pathogenesis of cystic fibrosis. Lancet 1993; 341: 1065–1069.
2. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075–1082.
3. Descamps-Latscha B, Döring G, Galanaud P, Lenoir G, Navarro J, Schaffar L. Inflammation in Cystic Fibrosis. Med Inflamm 1996; 5: 121–143.
4. Auerbach RS, Williams M, Kirkpatrick JA, Cotten HR. Alternate day prednisolone reduces the morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; II: 686–688.
5. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 331: 848–854.
6. Levy M, Spino M, Reid E. Colchicine: a state of the art review. Pharmacol Therapeut 1991; 1: 196–211.
7. Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 1985; 260: 17432–17436.
8. Higgins CF. ABC transporters: from microorganisms to man. Ann Rev Biol 1992; 8: 67–113.
9. Tommassini R, Evers R, Vogt E, et al. The human multidrug resistance-associated protein functionally complements the yeast cadmium resistance factor 1. Proc Natl Acad Sci USA 1996; 93: 6743–6748.
10. Lallemand JY, Steven V, Anneceau JP, Boucher J, Blanquet S, Barthe J, Lenoir G. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet 1997; 350: 711–712.
11. Stern RC. The diagnosis of cystic fibrosis. N Engl J Med 1997; 336: 487–491.
12. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158: 220–225.
13. Kelly SJ, Uri AJ, Freeland HS, et al. Effects of colchicine on IgE-mediated early and late airway reactions. Chest 1995; 107: 985–991.
14. Dallaverde E, Fan PT, Chang YH. Mechanism of action of colchicine. V. Neutrophil adherence and phagocytosis in patients with acute gout treated with colchicine. J Pharmacol Exp Ther 1982; 223: 197–202.
15. Peters-Golden M, McNish RW, Davis JA, et al. Colchicine inhibits arachidonate release and 5-lipoxygenase action in alveolar macrophages. J Pharmacol Exp Ther 1996; 271: 6 Pt 1, L1004–1015.
16. Entzian P, Schlaak M, Seitzer U, et al. Antinflammatory and anti fibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997; 175: 41–51.
17. Vollerth V, Wielandi AM, Acuna C, et al. Effect of colchicine and heat shock on multidrug resistance gene and P-glycoprotein expression in rat liver. J Hepatol 1994; 21: 754–763.
18. Elenko dova A, Kalpakova ES, Abdrjashitov RI, Stavrovskaya AA. Colchicine resistance and enhancement of P-glycoprotein activity after cultivation of drug-sensitive cells with multidrug resistant variants. Cell Biol Int 1995; 19(2): 113–119.
19. Wei LY, Stuts MJ, Hoffman MM, Roepe PD. Overexpression of the CFTR in NIH 3T3 cells lowers membrane potential and intracellular pH and confers a multidrug resistance phenotype. Biochem J 1995; 315: 883–895.
20. Lindsdell P, Hannahahn JW. Glutathione permeability of CFTR. Am J Cell Physiol 1998; 275(4): C325–C326.
21. Lindsdell P, Hannahahn JW. Adenosine triphosphate dependent asymmetry of anion permeation in cystic fibrosis transmembrane conductance regulator chloride channel. J Gen Physiol 1998; 111: 601–614.
22. Abschuler EL. Azithromycin, the multidrug-resistant protein, and cystic fibrosis. Lancet 1998; 351: 1286.

Acknowledgement: This work was supported by the association 'ABCF Protéine'.

Received 17 November 1998; accepted in revised form 18 December 1998

Mediators of Inflammation · Vol 8 · 1999 · 15